NASDAQ: KIDS · Industrial Applications and Services · 3 alerts · CIK 1425450
Share price
$31.50Close, Nov 16
Market cap
$822M
Shares outstanding
26.11MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Orthopediatrics Corp filings on SEC EDGAR ↗
OrthoPediatrics Corp. reported net revenue of $72.7 million for the third quarter of 2026, a 19% increase compared to the same period in 2025. While the company remains in a net loss position ($5.9 million for Q3 2026), it significantly narrowed its operating loss from $9.4 million to $4.2 million year-over-year.
OrthoPediatrics Corp. filed a formal investor presentation dated October 2026 to be used by executive officers in upcoming meetings with investors and analysts. The presentation includes strategic highlights and non-GAAP financial measures such as Adjusted EBITDA and free cash flow. The filing serves as a Regulation FD disclosure for the company's ongoing investor outreach efforts.
OrthoPediatrics reported record Q3 2026 revenue of $72.7 million, a 19% increase year-over-year, driven by strong growth in its Trauma & Deformity and Scoliosis segments. The company also generated positive free cash flow of $1.6 million and raised its full-year 2026 revenue guidance to a range of $270 million to $273 million.
Term
Q3 2026
“In the third quarter, we continued to build on the momentum in our business, gaining share in Trauma and Deformity and Scoliosis globally, and continued substantial progress with our OPSB strategy. This quarter, we not only drove revenue growth, but we continued to improve profitability, and generated positive free cash flow. We remain confident in our ability to continue to drive these metrics forward.”
David Bailey, President & CEO
“Our innovation super cycle is an important part of that opportunity, with a strong pipeline of new products coming over the next several years that are expected to deliver higher value and improved capital efficiency. We believe these launches will be an important driver of our financial performance as we bring new solutions to more surgeons and hospitals.”